This trial is evaluating whether Aerobic Training will improve 5 primary outcomes and 52 secondary outcomes in patients with Medulloblastoma. Measurement will happen over the course of baseline and 12 weeks post-randomization.
This trial requires 660 total participants across 8 different treatment groups
This trial involves 8 different treatments. Aerobic Training is the primary treatment being studied. Participants will be divided into 8 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The risk of getting medulloblastoma increases with a family history of cancer, having a sibling with a cancer diagnoses, previous maternal cancer at a young age, and having a first-born child that has tumours such as leukemia, glioblastoma multiforme or rhabdomyosarcoma. Exposure to ionising radiation and tobacco smoking before birth are also risk factors." - Anonymous Online Contributor
"There is currently insufficient clinical evidence to show a cure potential for m-B cell lymphoma. The development of specific targeted treatment in selected patients may allow a substantial change in long-term prognosis for this disease." - Anonymous Online Contributor
"Many patients with medulloblastoma require extensive surgery, radiation and chemotherapy. There are no cures for the disease. There are several types of chemotherapy available, including standard doses of cisplatin and newer drugs such as carboplatin. Other potentially curative treatments for medulloblastoma include high-intensity conditioning regimens followed by autologous stem cell transplantation or high-dose chemotherapy followed by autologous stem cell transplantation. Autologous stem cell transplantation has been done for patients with advanced tumors and is being explored as a potentially curative option for patients with earlier diagnoses of medulloblastoma." - Anonymous Online Contributor
"Patients with medulloblastoma present with a variety of signs and symptoms. Although headache is common in patients with medulloblastoma, the most common presenting symptom is brain swelling due to mass effect. There may be a correlation between increased intracranial pressure and the presence of brain metastases. Although leukemia is considered an important risk factor for medulloblastoma, in our experience, headache is not a risk factor." - Anonymous Online Contributor
"There are two types of medulloblastoma: sporadic medulloblastoma and neurofibromatosis type 1 medulloblastoma. Both types arise from primitive neuroectodermal cells that have lost normal differentiation processes during embryogenesis, resulting in the formation of tumors from undifferentiated cerebellar tissue. The clinical features, prognosis and response to treatment differ for the two types of medulloblastoma. In children with neurofibromatosis type 1 medulloblastoma and metastatic medulloblastoma, there are significant differences in survival rate and response to treatment compared with those with sporadic tumors from a similar grade and stage of disease." - Anonymous Online Contributor
"Around 3,500 children in the US are diagnosed with medulloblastoma each year, making it the second most common cancer in children in the United States and the second most common cause of childhood cancer-related mortality. In the United Kingdom, medulloblastoma made up 8.510 in children under 15 years of age and 20.810 in children aged 15 to 19 years in 1984. This number was almost 10-fold greater in children under 15-years-old and nearly 20-fold in those aged 15-39. In the US, children under the age of 10 were 2." - Anonymous Online Contributor
"Combined high-dose-rate brachytherapy and radiation boost are safe and effective alternatives to standard radiation intensification schedule for treating primary CNS tumors to reduce both acute and late effects of CNS radiation to minimize treatment-related complications. Because of potential benefits including reduced acute toxicity and neurocognitive outcomes, these techniques could become the standard-of-care therapy for patients with medically inoperable primary CNS tumors." - Anonymous Online Contributor
"In this analysis, it was demonstrated that the addition of primary c-kit pathway inhibitors to c-kit-targeting treatments might decrease the incidence of cns-is, particularly of CNS-related tumor recurrences. This promising regimen warrants validation in a randomized controlled trial." - Anonymous Online Contributor
"Although the incidence of medulloblastoma continues to increase among black children in the United States, there is no increased risk of medulloblastoma among children of other races." - Anonymous Online Contributor
"The most recent trials reported in this database have confirmed the role of [chemotherapy plus the addition and maintenance of a new CNS site of consolidation] in the treatment of children with medulloblastoma. Further clinical trials are required. Trial registration. Trials registration. com." - Anonymous Online Contributor
"CSI is an important treatment for children with high-risk medulloblastoma regardless of other chemotherapy regimens. CSI alone improves event-free survival and decreases the rate of children with poor outcome at 5 years, even in those with only a single high-risk factor." - Anonymous Online Contributor
"Findings from a recent study demonstrates high frequency of mutations in TP53 but also in NTRK3. This is the first study to suggest a direct link between NTRK3 mutations, which are frequently observed in medulloblastomas, and high level TP53 mutation in the development of this neoplasm. As a new, independent marker, NTRK3 could help to identify patients at risk to have poorer prognosis and to guide further intensive treatment approaches." - Anonymous Online Contributor